Heart Center Dresden to Be First Commercial Clinical Site for Imricor
Imricor announced today that it signed its first commercialization contract for the Advantage-MR EP Recorder/Stimulator System and supporting Vision-MR devices1 with the Heart Center Dresden in Germany. This agreement places the Heart Center Dresden at the forefront of clinical advancement for MRI-guided cardiac ablations and establishes the hospital as a world leader in the growing field of interventional cardiac magnetic resonance (iCMR).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181010005779/en/
Dr. Christopher Piorkowski in the newly installed iCMR lab at the Heart Center Dresden. (Photo: Heart Center Dresden)
“Here at the Heart Center Dresden, we are proud to have the opportunity and the commitment to pioneer forefront research in the field of cardiac arrhythmia treatment,” said Dr. Christopher Piorkowski, Head of Electrophysiology at the Heart Center Dresden. “Having recently completed the successful installation of one of the most advanced cardiac MRI setups in the world, we are now preparing for the first routine clinical applications of catheter ablation within the MRI. We expect groundbreaking new insights and an innovative push into our understanding and treatment of patients with structural heart disease and related cardiac arrhythmias.”
Imricor’s Advantage-MR System and Vision-MR devices are state-of-the-art cardiac ablation tools that allow physicians to perform procedures under real-time MRI guidance. Unlike conventional x-ray guided procedures, ablations guided by MRI allow physicians to individualize the treatment strategy for each patient’s unique cardiac structure and substrate as well as assess lesion quality and fill gaps in ablation lines during the initial procedure. These benefits have the potential to improve patient outcomes and provide safer, more cost-effective treatment – all in an environment that is free of radiation for both the patient and physician.
Prof. Dr. Bärbel Held, Managing Director of the Heart Center Dresden, commented, “I am very proud, together with Imricor and Dr. Piorkowski, for the heart center in Dresden to introduce and apply such an innovation. For our patients, this will be a big advantage in the treatment of cardiac arrhythmias. This is what the Heart Center Dresden stands for.”
“This is an exciting milestone for both Imricor and the Heart Center Dresden. It marks the beginning of the commercial clinical application of iCMR-guided ablations and a new age for interventional cardiology,” said Steve Wedan, CEO of Imricor. “Prof. Held has a brilliant vision for the future of medicine at Heart Center Dresden, and we couldn’t be more thrilled to be working with Dr. Piorkowski and his extraordinary team as we usher in this new age together.”
1Delivery of Vision-MR devices will commence upon CE mark approval of devices.
Imricor Medical Systems is a privately held company committed to unlocking the potential of interventional cardiac magnetic resonance (iCMR) by delivering MR-compatible systems and devices that allow physicians to perform cardiac ablations under real-time MRI-guidance.
About the Heart Center Dresden
The Heart Center Dresden is a University Hospital owned by the Sana Kliniken AG. The Heart Center is structured into three departments – Cardiac Surgery, Cardiology, and Electrophysiology. Over 650 employees provide in-patient and out-patient services for nearly 25,000 patients per year. In alliance with the Technical University Dresden, medical education as well as research and sciences are integral parts of the portfolio.
CAUTION: The Advantage-MR™ EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MR™ Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor devices are not yet approved for use in humans.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
PMI Launches Search for Next President and CEO22.10.2018 14:00 | Pressemelding
Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d
E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 13:43 | Pressemelding
E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t
Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 12:00 | Pressemelding
Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t
Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 11:50 | Pressemelding
To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t
Sony Corporation Selects ANAQUA for IP Management22.10.2018 11:00 | Pressemelding
Anaqua, Inc., the leading provider of innovation and intellectual property (IP) management solutions, today announced that multinational technology company Sony Corporation has entered into a multi-year agreement to use the ANAQUA software to manage its patent and trademark portfolios. Sony is one of the world’s largest technology and entertainment companies, with products spanning consumer electronics, smart phones, game and network services, financial services, and professional products. “We are excited to welcome one of the world’s largest companies and IP leaders to Anaqua’s growing client community,” said Bob Romeo, CEO of Anaqua. “Sony’s decision to strategically partner with Anaqua for their IP Management system reinforces our continued investment in the APAC market.” ABOUT ANAQUA The most innovative companies in the world innovate with Anaqua. Its simplified software platform combines insight from big data analytics with critical tools, best practice workflows and advanced serv
Dentsu Aegis Network Announces the Acquisition of Namics AG22.10.2018 11:00 | Pressemelding
Dentsu Aegis Network today announces that it has signed a definitive agreement to acquire Namics AG, a leading full-service digital agency in Switzerland and Germany. Following the acquisition, which is subject to approval from the German competition authority, the company will become ‘Namics - A Merkle Company’. Namics’ digital experience, creative and service design expertise complements Merkle’s already significant customer experience (CX) and marketing technology practice in the region. An important step in Merkle’s strategy to increase its global footprint, it provides further scale and depth to Merkle’s people-based marketing capabilities, in particular in the areas of business transformation strategy, digital consulting and technology implementation across Adobe Experience Cloud, Sitecore, Salesforce and SAP and other leading technology partners. All Namics‘ 550 digital specialists based in Frankfurt, Hamburg, Munich, St. Gallen, Zurich and Belgrade will join Merkle, bringing it